Growth Metrics

Moderna (MRNA) Change in Cash (2018 - 2026)

Moderna (MRNA) has disclosed Change in Cash for 9 consecutive years, with -$688.0 million as the latest value for Q1 2026.

  • For Q1 2026, Change in Cash fell 127.06% year-over-year to -$688.0 million; the TTM value through Mar 2026 reached $283.0 million, up 163.6%, while the annual FY2025 figure was $668.0 million, 166.87% up from the prior year.
  • Change in Cash hit -$688.0 million in Q1 2026 for Moderna, down from $1.5 billion in the prior quarter.
  • Across five years, Change in Cash topped out at $1.5 billion in Q4 2025 and bottomed at -$2.2 billion in Q2 2022.
  • Average Change in Cash over 5 years is -$291.2 million, with a median of -$147.0 million recorded in 2025.
  • Year-over-year, Change in Cash plummeted 1450.93% in 2022 and then skyrocketed 1228.0% in 2024.
  • Moderna's Change in Cash stood at $176.0 million in 2022, then crashed by 114.2% to -$25.0 million in 2023, then surged by 1228.0% to $282.0 million in 2024, then skyrocketed by 418.79% to $1.5 billion in 2025, then tumbled by 147.03% to -$688.0 million in 2026.
  • According to Business Quant data, Change in Cash over the past three periods came in at -$688.0 million, $1.5 billion, and -$147.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.